Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | ELARA: tisagenlecleucel in patients with relapsed/refractory follicular lymphoma

Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, touches on the Phase II ELARA trial which looks at the efficacy and safety of tisagenlecleucel (tisa-cel) in patients with relapsed follicular lymphoma (NCT03568461). Dr Riedell emphasizes the encouraging results of the trial with a favourable complete response rate observed. However, follow-up is ideal to understand the long-term outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Disclosures

Peter A. Riedell, MD, reports research support/funding from Celgene/BMS, Kite Pharma, Inc./Gilead, MorphoSys, Calibr, Xencor, Tessa Therapeutics, and Novartis Pharmaceuticals Corporation; speaker’s bureau from Kite Pharma, Inc./Gilead and Bayer; consultancy on advisory boards from Verastem Oncology, Novartis Pharmaceuticals Corporation, Celgene/BMS, BeiGene, Karyopharm Therapeutics Inc., Takeda Pharmaceutical Company, and Bayer; honoraria from Novartis Pharmaceuticals Corporation.